Glycosmedia - an international diabetes news service from the UK
Archived News
April 27th 2012
  Development of a minimal set of prescribing quality indicators for diabetes management on a general practice level
  We showed that a minimal set of prescribing quality indicators for type 2 diabetes mellitus care should not just focus on the management of different clinical risk factors but also reflect different steps of treatment intensification (Pharmacoepidemiology and Drug Safety)
  Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor-based electronic health record
  Clinical and demographic characteristics influence choice and duration of initial oral hypoglycemic treatment as well as regimen changes (Pharmacoepidemiology and Drug Safety)
  New tool to recognise depression in diabetes
  A new e-skill module to enable nurses and GP’s to spot the signs and manage depression in patients with diabetes launched at Guy’s Hospital (King’s College London)
  Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes
  More than 40% of very young children were able to safely use CGM on a near-daily basis after 6 months. CGM demonstrated frequent hyperglycemic excursions, with a large variability in glucose readings. Although improvement in glycemic control was not detected in the group as a whole, parental satisfaction with CGM was high (Pediatric Diabetes)
  Evaluation of a combined blood glucose monitoring and gaming system (Didget®) for motivation in children, adolescents, and young adults with type 1 diabetes
  Most HCPs agreed that the system fulfilled a need in diabetes management. In conclusion, the Didget® system was precise and clinically accurate in the hands of children, adolescents, and young adults with type 1 diabetes (Pediatric Diabetes)
  Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study
  Improvements in the attainment of guidelines-recommended targets in patients with type 2 diabetes followed for a 12-month period in the primary care setting; however, many individuals still failed to achieve and especially maintain optimal goals for therapy, particularly the triple target. Results of the multivariable analysis reinforce the need to address barriers to improve diabetes care, particularly in more susceptible groups (International Journal of Clinical Practice)
  Impact of a single one to one education on glycaemic control in patients with diabetes
  A single episode of one to one diabetic and dietetic education to subjects with poor diabetic control is effective in improving short and long term diabetic control upto 1 year with male patients having a better response (Journal of Diabetes)
  Diabetes threatens to 'bankrupt' NHS within a generation
  Treatment will use £16.9bn of budget as the number of diabetics rises from 3.8m patients to 6.25m by 2035 (Guardian, UK)
  Vascular stem cells in diabetic complications: evidence for a role in the pathogenesis and the therapeutic promise
  In this article, we summarize the vascular changes that occur in diabetic complications highlighting some of the common features, the key findings that illustrate an important role of vascular stem cells (VSCs) in the pathogenesis of chronic diabetic complications, and provide mechanisms by which these cells can be used for therapy - provisional PDF (Cardiovascular Diabetology)
  KATP channel mutations in infants with permanent diabetes diagnosed after 6 months of life
  KATP channel mutations are an uncommon cause of diabetes in infants presenting after 6 months. However, given the potential clinical benefit from identifying a KATP channel mutation, we recommend that KATP mutation testing should be routinely extended to infants diagnosed up to 9 month (Pediatric Diabetes)
  Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies
  Screening for islet autoantibodies in children likely leads to earlier diabetes diagnosis resulting in less complications at diagnosis. However, no substantial benefit in the clinical outcome during the first 5 yr after diagnosis was observed (Pediatric Diabetes)
  European Medicines Agency recommends authorisation of novel treatment for type 2 diabetes
  The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of a marketing authorisation for Forxiga (dapagliflozin), a novel treatment for type 2 diabetes mellitus (European Medicines Agency)
  Effects of incretins on blood pressure: A promising therapy for type 2 diabetes mellitus with hypertension
  We conclude that incretins can lower blood pressure of T2DM patients, independent of weight loss, and will surely improve the prognosis of these patients (Journal of Diabetes)
  What's in a P -value?
  When you read articles looking for important results between treatment groups or populations of patients, how do you know what differences between the populations are significant? Here is where the mystical "p-value" comes into play. I wonder how many of our readers actually know what a p-value represents? (PRESENT Podiatry)
© Copyright Glycosmedia Partnership